JP2020500181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500181A5 JP2020500181A5 JP2019523769A JP2019523769A JP2020500181A5 JP 2020500181 A5 JP2020500181 A5 JP 2020500181A5 JP 2019523769 A JP2019523769 A JP 2019523769A JP 2019523769 A JP2019523769 A JP 2019523769A JP 2020500181 A5 JP2020500181 A5 JP 2020500181A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- cdr3l
- cdr3h
- cdr1h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 claims 32
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 16
- 239000002955 immunomodulating agent Substances 0.000 claims 12
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 7
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 7
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 102000046935 human TNFRSF17 Human genes 0.000 claims 7
- 229960003433 thalidomide Drugs 0.000 claims 7
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 6
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 6
- 230000001024 immunotherapeutic effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- VVHQVXXPZDALDV-BOXHHOBZSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione;hydrochloride Chemical compound Cl.O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 VVHQVXXPZDALDV-BOXHHOBZSA-N 0.000 claims 2
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 2
- 229960002204 daratumumab Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 229950007752 isatuximab Drugs 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229950010773 pidilizumab Drugs 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229950007213 spartalizumab Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196874.8 | 2016-11-02 | ||
| EP16196874 | 2016-11-02 | ||
| PCT/EP2017/078109 WO2018083204A1 (en) | 2016-11-02 | 2017-11-02 | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500181A JP2020500181A (ja) | 2020-01-09 |
| JP2020500181A5 true JP2020500181A5 (OSRAM) | 2020-12-10 |
| JP7267914B2 JP7267914B2 (ja) | 2023-05-02 |
Family
ID=57226831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523769A Active JP7267914B2 (ja) | 2016-11-02 | 2017-11-02 | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11124577B2 (OSRAM) |
| EP (2) | EP3535295A1 (OSRAM) |
| JP (1) | JP7267914B2 (OSRAM) |
| KR (1) | KR102687833B1 (OSRAM) |
| CN (1) | CN110167964B (OSRAM) |
| AU (1) | AU2017353427A1 (OSRAM) |
| BR (1) | BR112019008426A2 (OSRAM) |
| CA (1) | CA3041183A1 (OSRAM) |
| CL (1) | CL2019001198A1 (OSRAM) |
| EA (1) | EA201990787A1 (OSRAM) |
| IL (1) | IL266424B2 (OSRAM) |
| MX (1) | MX2019004621A (OSRAM) |
| SG (1) | SG11201903359RA (OSRAM) |
| WO (1) | WO2018083204A1 (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| PT3411402T (pt) | 2016-02-03 | 2022-02-01 | Amgen Inc | Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3 |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| IL267485B2 (en) | 2016-12-21 | 2024-01-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies and uses thereof |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019053613A2 (en) * | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020009116A (es) * | 2018-03-02 | 2020-12-07 | Cdr Life Ag | Proteinas triespecificas de union a antigenos. |
| MX2020010267A (es) | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
| AU2019270624B2 (en) * | 2018-05-16 | 2024-05-02 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics |
| CN113713095B (zh) * | 2018-05-23 | 2025-07-15 | 细胞基因公司 | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 |
| TWI848951B (zh) | 2018-06-01 | 2024-07-21 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| CN112105391B (zh) * | 2018-06-26 | 2024-05-14 | 爱必乐生物公司 | 抗-bcma抗体及其用途 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| CN109053892B (zh) * | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AU2019351811B2 (en) * | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| WO2020089437A1 (en) * | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
| WO2020146423A1 (en) * | 2019-01-07 | 2020-07-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| WO2020219978A1 (en) * | 2019-04-25 | 2020-10-29 | Celgene Corporation | Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| CA3144324A1 (en) * | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| US20230057602A1 (en) * | 2019-11-05 | 2023-02-23 | Bristol-Myers Squibb Company | Methods of treatment with antibodies against bcma and cd3 |
| BR112022008652A2 (pt) * | 2019-11-05 | 2022-07-19 | Hoffmann La Roche | Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção |
| HRP20241281T1 (hr) | 2019-11-11 | 2024-12-06 | Amgen Research (Munich) Gmbh | Režim doziranja anti-bcma sredstava |
| EP4069373A1 (en) * | 2019-12-06 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| BR112022024483A2 (pt) * | 2020-04-29 | 2023-02-07 | Teneoone Inc | Métodos para tratar mieloma múltiplo |
| IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Methods for treating multiple myeloma |
| MX2022014180A (es) * | 2020-05-13 | 2022-12-02 | Pfizer | Metodos, terapias y usos para tratar cancer. |
| MX2022014426A (es) * | 2020-05-19 | 2023-04-21 | Janssen Biotech Inc | Composiciones que comprenden una terapéutica de redirección de células t y un inhibidor de la ruta de adhesión de vla-4. |
| JP2023540795A (ja) * | 2020-09-14 | 2023-09-26 | ファイザー・インク | がんを処置するための方法、治療、および使用 |
| WO2022061098A1 (en) * | 2020-09-18 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
| CN112159476B (zh) * | 2020-10-10 | 2022-08-02 | 中国药科大学 | 一种用于多发性骨髓瘤的双特异性抗体及其应用 |
| WO2022135468A1 (zh) * | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 抗bcma×cd3双特异性抗体及其用途 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| EP4324853A4 (en) * | 2021-04-15 | 2025-07-16 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | MULTI-SPECIFIC ANTIBODY TARGETING BCMA |
| CN119569887A (zh) * | 2021-06-24 | 2025-03-07 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| AU2022380722A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN119031933B (zh) * | 2022-04-12 | 2025-08-26 | 正大天晴(广州)医药有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
| CN117003871A (zh) * | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| US20240228650A9 (en) | 2022-05-06 | 2024-07-11 | Ichnos Sciences SA | CD3/BCMA/CD38 Trispecific Antibodies |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| AU2024237201A1 (en) * | 2023-03-10 | 2025-09-18 | Joint Stock Company "Biocad" | Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025240287A1 (en) * | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0807173B1 (en) | 1994-12-30 | 2007-08-08 | Planet Biotechnology, Inc. | Methods for producing immunoglobulins containing protection proteins in plants and their use |
| GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2176574T3 (es) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DE60005135T3 (de) | 1999-01-07 | 2015-04-09 | Zymogenetics, Inc. | Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| CA2457636C (en) | 2001-08-10 | 2012-01-03 | Aberdeen University | Antigen binding domains |
| EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| ES2283368T3 (es) | 2001-11-14 | 2007-11-01 | Affimed Therapeutics Ag | Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos. |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| PL224786B1 (pl) | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
| AU2004215489B2 (en) | 2003-02-25 | 2010-07-15 | Nykode Therapeutics ASA | Modified antibody |
| CA2533830A1 (en) | 2003-08-07 | 2005-02-24 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CA2567655C (en) | 2004-06-02 | 2015-06-30 | Diatech Pty Ltd | Binding moieties based on shark ignar domains |
| AU2006204459B2 (en) | 2005-01-05 | 2012-11-01 | F-Star Therapeutics Limited | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| MX2007013924A (es) | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc. |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| WO2007019620A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| WO2007031875A2 (en) | 2005-08-26 | 2007-03-22 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| CN101466733A (zh) | 2006-04-14 | 2009-06-24 | 特鲁比昂药品公司 | 包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白 |
| IL177158A0 (en) | 2006-07-30 | 2008-01-20 | Assaf Klar | Method for designing and implementing improved longitudinal flexibility multilayered pipeline |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP2235061A1 (en) | 2008-01-15 | 2010-10-06 | F. Hoffmann-La Roche AG | Afucosylated antibodies against ccr5 and their use |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| DK2842575T3 (da) | 2008-03-18 | 2017-11-27 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| EP2283355A2 (en) | 2008-04-25 | 2011-02-16 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| HRP20161194T1 (hr) | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| GB0914330D0 (en) * | 2009-08-17 | 2009-09-30 | Univ Dublin City | A method of predicting response to thalidomide in multiple myeloma patients |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| KR102232153B1 (ko) | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2014368383B2 (en) | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| KR102411972B1 (ko) * | 2014-08-04 | 2022-06-23 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
| WO2016040238A1 (en) | 2014-09-08 | 2016-03-17 | Celgene Corporation | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| WO2017002145A1 (en) * | 2015-06-30 | 2017-01-05 | Nec Corporation | Base station, communication system, method, and program |
| PT3331910T (pt) * | 2015-08-03 | 2020-03-24 | Engmab Sarl | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano |
-
2017
- 2017-11-02 US US16/346,771 patent/US11124577B2/en active Active
- 2017-11-02 MX MX2019004621A patent/MX2019004621A/es unknown
- 2017-11-02 AU AU2017353427A patent/AU2017353427A1/en not_active Abandoned
- 2017-11-02 WO PCT/EP2017/078109 patent/WO2018083204A1/en not_active Ceased
- 2017-11-02 BR BR112019008426A patent/BR112019008426A2/pt unknown
- 2017-11-02 SG SG11201903359RA patent/SG11201903359RA/en unknown
- 2017-11-02 CN CN201780081998.4A patent/CN110167964B/zh active Active
- 2017-11-02 JP JP2019523769A patent/JP7267914B2/ja active Active
- 2017-11-02 KR KR1020197015708A patent/KR102687833B1/ko active Active
- 2017-11-02 CA CA3041183A patent/CA3041183A1/en active Pending
- 2017-11-02 EP EP17797905.1A patent/EP3535295A1/en not_active Withdrawn
- 2017-11-02 EA EA201990787A patent/EA201990787A1/ru unknown
- 2017-11-02 IL IL266424A patent/IL266424B2/en unknown
- 2017-11-02 EP EP23204427.1A patent/EP4295918A3/en not_active Withdrawn
-
2019
- 2019-04-30 CL CL2019001198A patent/CL2019001198A1/es unknown
-
2021
- 2021-06-24 US US17/304,702 patent/US20220002427A1/en not_active Abandoned
- 2021-06-24 US US17/304,683 patent/US20220017631A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500181A5 (OSRAM) | ||
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| KR102470294B1 (ko) | 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합 | |
| FI3796912T3 (fi) | Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön | |
| JP2017537892A5 (OSRAM) | ||
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| WO2022187539A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen | |
| JP2019536430A5 (OSRAM) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| CA2984464C (en) | Treatment for multiple myeloma (mm) | |
| KR20230008197A (ko) | 암을 치료하기 위한 방법, 요법 및 용도 | |
| JP2018506550A5 (OSRAM) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2015534579A5 (OSRAM) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2009519257A5 (OSRAM) | ||
| JP2020510039A5 (OSRAM) | ||
| JP2014502955A5 (OSRAM) | ||
| JP2012102122A5 (OSRAM) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2010500370A5 (OSRAM) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2017534645A5 (OSRAM) | ||
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2018502068A5 (OSRAM) |